NCT01374139 - Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)

Interventions

DRUG

Bosutinib

5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition

DRUG

Bosutinib

4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition

Trial Locations (1)

Pfizer Investigational Site, Singapore